Example: barber
of the Patient
Dec 15, 2021 · The predominant feature of ET is thrombocytosis (increased platelet count). A Janus kinase 2 (JAK2) enzyme mutation, JAK2 3V617F, is present in approximately 50 -60% of patients living with ET.,4 Additionally, calreticulin (CALR) mutation is present in approximately 20 -25% of ET patients.4 Common
Tags:
Information
Domain:
Source:
Link to this page: